Early Human ADME Using Microdoses and Microtracers: Bioanalytical Considerations

• Andersson T , BredbergE, EricssonH, SjobergH. An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metab. Dispos. 32(7), 715–721 (2004).
   PubMed Web of Science ®Google Scholar
• Grass G , SinkoP. Physiologically-based pharmacokinetic simulation modeling. Adv. Drug Deliv. Rev. 54, 433–451 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson S , Luffer-AtlasD, KnadlerM. Predicting circulating human metabolites: how good are we? Chem. Res. Toxicol. 22, 243–256 (2009).
   PubMed Web of Science ®Google Scholar
• Lappin G , GarnerRC, MeyersT, PowellJ, VarleyP. Novel use of accelerator mass spectrometry for the quantification of low levels of systemic therapeutic recombinant protein. J. Pharm. Biomed. Anal. 41(4), 1299–1302 (2006).
   PubMed Web of Science ®Google Scholar
• Lappin G , KuhnzW, JochemsenRet al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharmacol. Ther. 80, 203–215 (2006).
   PubMed Web of Science ®Google Scholar
• Lappin G , RowlandM, GarnerRC. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin. Drug Metab. Toxicol. 2(3), 419–427 (2006).
   PubMed Web of Science ®Google Scholar
• Balani SK , NagarajaNV, QianMGet al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography–tandem mass spectrometry. Drug Metab. Dispos. 34(3), 384–388 (2006).
   PubMed Web of Science ®Google Scholar
• Ings R . Microdosing. A valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis1(7), 1293–1305 (2009).
   PubMed Web of Science ®Google Scholar
• Madan A , O’brienZ, WenJet al. A pharmacokinetic evaluation of five h(1) antagonists after an oral and intravenous microdose to human subjects. Br. J. Clin. Pharmacol. 67(3), 288–298 (2009).
   PubMed Web of Science ®Google Scholar
• Vuong L , RuckleJ, BloodAet al. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J. Pharm. Sci. 97(7), 2833–2843 (2008).
   PubMed Web of Science ®Google Scholar
• Lappin G , GarnerRC. The use of accelerator mass spectrometry to obtain early human ADME/PK data. Expert Opin. Drug Metab. Toxicol. 1(1), 23–31 (2005).
   PubMedGoogle Scholar
• Lappin G , StevensL. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 4(8), 1021–1033 (2008).
   PubMed Web of Science ®Google Scholar
• Gilman S , GeeS, HammockBet al. Analytical performance of accelerator mass spectrometry and liquid scintillation counting for detection of 14C-labeled atrazine metabolites in human urine. Anal. Chem. 70(16), 3463–3469 (1998).
   PubMed Web of Science ®Google Scholar
• Rickert D , DingleyK, UbickE, DixK, MolinaL. Determination of the tissue distribution and excretion by accelerator mass spectrometry of the nonadecapeptide 14C-moli1901 in beagle dogs after intratracheal instillation. Chem. Biol. Interact. 155(1-21-22), 55–61 (2005).
   PubMed Web of Science ®Google Scholar
• Sarapa N , HsyuPH, LappinG, GarnerRC. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J. Clin. Pharmacol. 45(10), 1198–1205 (2005).
   PubMed Web of Science ®Google Scholar
• Smith DA , ObachRS. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem. Res. Toxicol. 22(2), 267–279 (2009).
   PubMed Web of Science ®Google Scholar
• Walgren J , MitchellM, ThompsonD. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35(4), 325–361 (2005).
   PubMed Web of Science ®Google Scholar
• Mutlib A , GersonR, MeunierPet al. The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol. Appl. Pharmacol. 169(1), 102–113 (2000).
   PubMed Web of Science ®Google Scholar
• Williams J , AnderssonT, AnderssonTet al. Phrma white paper on ADME pharmacogenomics. J. Clin. Pharmacol. 48(7), 849–889 (2008).
   PubMed Web of Science ®Google Scholar
• Grossman I . ADME pharmacogenetics. Current practices and future outlook. Expert Opin. Drug Metab. Toxicol. 5(5), 449–462 (2009).
   PubMed Web of Science ®Google Scholar
• Sunzel M . Studies of the basic pharmacokinetic properties of a drug: a regulatory perspective. In:New Drug Development – Regulatory Paradigms for Clinical Pharmacology. Sahajwalla CG (Ed.). Center for Drug Evaluation and Research, FDA, North Potomac, MA, USA (2004).
   Google Scholar
• Baillie T , CayenM, FoudaHet al. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182(3), 188–196 (2002).
   PubMed Web of Science ®Google Scholar
• Roffey SJ , ObachRS, GedgeJI, SmithDA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab. Rev. 39(1), 17–43 (2007).
   PubMed Web of Science ®Google Scholar
• US FDA Centre for Drug Evaluation and Research. Guidance for Industry: Safety Testing of Drug Metabolites. (2008).
   Google Scholar
• ICH Harmonized Tripartite Guideline: M3(R2). Non-clinical Safety Studies for the Conduct of Human Cinical Trials and Marketing Authorization for Pharmaceuticals. (2009).
   Google Scholar
• Robinson WT , JacobsA. Metabolites in safety testing. Bioanalysis1(7), 1193–1200 (2009).
   PubMed Web of Science ®Google Scholar
• Vogel JS , SouthonJR, Nelson De, Brown TA. Performance of catalytically condensed carbon for use in accelerator mass spectrometry. Nucl. Instrum. Methods Phys. Res. B5(2), 289–293 (1984).
   Web of Science ®Google Scholar
• Vogel JS . Rapid production of graphite without contamination for biomedical AMS. Radiocarbon34(3), 344–350 (1992).
   Web of Science ®Google Scholar
• Ognibene T , BenchG, VogelJ, PeasleeG, MurovS. A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry. Anal. Chem. 75(9), 2192–2196 (2003).
   PubMed Web of Science ®Google Scholar
• Vogel JS , GiacomoJA, Schulze-KönigTet al. Accelerator mass spectrometry best practices for accuracy and precision in bioanalytical 14C measurements. Bioanalysis2(3), 477–490 (2010).
   Web of Science ®Google Scholar
• Keck BD , OgnibeneT, VogelJS. Analytical validation of accelerator MS for pharmaceutical development: the measurement of 14C isotope ratio. Bioanalysis2(3), 491–507 (2010).
   Web of Science ®Google Scholar
• Vogel J , TurteltaubK, FinkelR, NelsonD. Accelerator mass spectrometry. Anal. Chem. 67(11), 353A–359A (1995).
   PubMed Web of Science ®Google Scholar
• Garner R , BarkerJ, FlavellCet al. A validation study comparing accelerator ms and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J. Pharm. Biomed. Anal. 24(2), 197–209 (2000).
   PubMed Web of Science ®Google Scholar
• Young G , EllisW, AyrtonJ, HusseyE, AdamkiewiczB. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica31(8–9), 619–632 (2001).
   PubMed Web of Science ®Google Scholar
• Vogel J , LoveA. Quantitating Isotopic Molecular Labels with Accelerator Mass Spectromer. Burlingame AL (Ed.). Meth. Enzym. Academic Press, NY, USA, 402–423 (2005).
   Google Scholar
• Viswanathan C , BansalS, BoothBet al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962–1973 (2007).
   PubMed Web of Science ®Google Scholar
• US FDA Centre for Drug Evaluation and Research. Guidance for Industry: Bioanalytical Method Validation. (2001).
   Google Scholar
• ICH Harmonized Tripartite Guideline: Q2(R1). Validation of analytical procedures. Current Step 4 Version. (2005).
   Google Scholar
• Synal H , StockerM, SuterM. Micadas: a new compact radiocarbon ams system. Nucl. Instrum. Methods Phys. Res. B259(1), 7–13 (2007).
   Web of Science ®Google Scholar
• Bansal S , DestefanoA. Key elements of bioanalytical method validation for small molecules. AAPS J. 9(1), E109–E114 (2007).
   PubMed Web of Science ®Google Scholar
• Vishwanathan K , BabalolaK, WangJet al. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: Addressing metabolites in safety testing (mist) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem. Res. Toxicol. 22(2), 311–322 (2009).
   PubMed Web of Science ®Google Scholar
• Lappin G , SimpsonM, ShishikuraY, GarnerC. High-performance liquid chromatography accelerator mass spectrometry: Correcting for losses during analysis by internal standardization. Anal. Biochem. 378(1), 93–95 (2008).
   PubMed Web of Science ®Google Scholar
• Kiffe M . Radioactivity detectors for high-performance liquid chromatography in drug metabolism studies. J. Liq. Chromatogr. Relat. Technol. 31, 1593–1619 (2008).
   Web of Science ®Google Scholar
• Vogel J , LohstrohP, KeckB, DuekerS. Quantitating drug metabolism with accelerator mass spectrometry. In:Mass Spectrometry in Drug Metabolism and Disposition: Basic Principles and Applications. Lee M, Zhu M (Ed.). John Wiley & Sons, Hoboken, NJ, USA (2009).
   Google Scholar
• Leclercq L , CuyckensF, MannensG, De Vries R, Timmerman P, Evans D. Which human metabolites have we mist? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem. Res. Toxicol. 22(2), 280–293 (2009).
   PubMed Web of Science ®Google Scholar

Website

• European Union Microdose AMS Partnership Programme www.eumapp.com
   Google Scholar